朗姿股份(002612.SZ):申炳雲承諾待其減持完畢後 以不低於5億元助力公司醫美業務的戰略實施
格隆匯6月8日丨朗姿股份(002612.SZ)公佈,公司於2021年6月8日收到公司實際控制人、控股股東之一致行動人申炳雲發來的《承諾函》,現將具體情況公吿如下:
為支持公司醫美事業的發展,結合申炳雲資產規劃,申炳雲同意並承諾,待其所持朗姿股份股票減持計劃實施完畢後,申炳雲將通過合規的途徑和合適的方式,以不低於5億元人民幣的金額,助力朗姿股份醫美業務的戰略實施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.